Menkes Disease Latest Advances

Menkes Disease: Another Example of Progress in the Development of Pharmaceuticals for Rare Childhood Diseases, But Much Still Remains to Be Done.

Journal: Clinical therapeutics

Published: February 24, 2026

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease.

Journal: The Journal of clinical investigation

Published: February 16, 2026

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease. Reply.

Journal: The Journal of clinical investigation

Published: February 16, 2026

Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

NON-REDUNDANT ROLES OF COPPER TRANSPORTERS ATP7A AND ATP7B IN NORADRENERGIC SIGNALING.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Deciphering Copper Homeostasis and Cuproptosis: Biological Mechanisms, Disease Connections, and Cutting-Edge Copper-Based Nanomedicine.

Journal: Molecular pharmaceutics

Published: February 02, 2026

Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.

Journal: Trends in pharmacological sciences

Published: January 28, 2026

Copper in Human Health and Disease: Insights from Inherited Disorders.

Journal: Physiology (Bethesda, Md.)

Published: November 10, 2025

Copper Homeostasis and Cuproptosis in Neurological Disorders.

Journal: Drug design, development and therapy

Published: November 08, 2025

CRISPR prime editing as a promising therapeutic avenue for Menkes disease: the next step in correcting ATP7A mutations.

Journal: Annals of medicine and surgery (2012)

Published: November 04, 2025

Whole genome sequencing from dried blood spots for newborn screening of Menkes disease and 36 other actionable inherited neurometabolic disorders.

Journal: Molecular genetics and metabolism

Published: October 31, 2025

From copper transport to cuproptosis: emerging therapeutic targets in cardiovascular disease.

Journal: Molecular and cellular biochemistry

Published: October 01, 2025

Menkes Disease Latest Advances

Find the Latest Research About Menkes Disease

Menkes Disease: Another Example of Progress in the Development of Pharmaceuticals for Rare Childhood Diseases, But Much Still Remains to Be Done.

Menkes Disease: Another Example of Progress in the Development of Pharmaceuticals for Rare Childhood Diseases, But Much Still Remains to Be Done.

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease.

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease.

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease. Reply.

Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease. Reply.

Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis.

Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis.

NON-REDUNDANT ROLES OF COPPER TRANSPORTERS ATP7A AND ATP7B IN NORADRENERGIC SIGNALING.

NON-REDUNDANT ROLES OF COPPER TRANSPORTERS ATP7A AND ATP7B IN NORADRENERGIC SIGNALING.

Deciphering Copper Homeostasis and Cuproptosis: Biological Mechanisms, Disease Connections, and Cutting-Edge Copper-Based Nanomedicine.

Deciphering Copper Homeostasis and Cuproptosis: Biological Mechanisms, Disease Connections, and Cutting-Edge Copper-Based Nanomedicine.

Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.

Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.

Copper in Human Health and Disease: Insights from Inherited Disorders.

Copper in Human Health and Disease: Insights from Inherited Disorders.

Copper Homeostasis and Cuproptosis in Neurological Disorders.

Copper Homeostasis and Cuproptosis in Neurological Disorders.

CRISPR prime editing as a promising therapeutic avenue for Menkes disease: the next step in correcting ATP7A mutations.

CRISPR prime editing as a promising therapeutic avenue for Menkes disease: the next step in correcting ATP7A mutations.

Whole genome sequencing from dried blood spots for newborn screening of Menkes disease and 36 other actionable inherited neurometabolic disorders.

Whole genome sequencing from dried blood spots for newborn screening of Menkes disease and 36 other actionable inherited neurometabolic disorders.

From copper transport to cuproptosis: emerging therapeutic targets in cardiovascular disease.

From copper transport to cuproptosis: emerging therapeutic targets in cardiovascular disease.